Measuring the Outcomes of International Oncology Regulatory Collaboration in Canada from 2019 to 2025: Project Orbis Authors: Jonathan Zaslavsky, David C Sealey Published: 2026 ABSTRACT AbstractProject Orbis, launched by the US FDA in 2019, enables collaboration among international regulatory agencies on cancer drug reviews. We assessed the regulatory impact of Project Orbis in Canada by analyzing publicly available data on marketing authorization applications (MAAs). We analyzed US‐Canada submission and approval gaps, time to regulatory decision, tumor areas, and sponsor involvement. From September 20, 2019 to the end of 2025, Health Canada approved 97 Orbis and 161 non‐Orbis oncology MAAs. Orbis MAAs had a shorter median submission gap than non‐Orbis MAAs, as well as a shorter median approval gap. Median time to decision was shorter for Orbis MAAs than non‐Orbis MAAs and was related to accelerated or standard review pathways. The time to decision was consistent with Health Canada's performance standards, and notably, Orbis type A median time to decision was similar for standard and priority review MAAs. Health Canada has been a highly active Project Orbis partner. Further research is needed to determine whether Orbis accelerates the overall time from regulatory filing to patient access to treatment, inclusive of health technology assessment and reimbursement negotiation processes. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? The FDA Oncology Center of Excellence publishes a listing of drug MAAs reviewed through Project Orbis. Current analyses of Project Orbis in Canada do not capture the full timeframe of pre‐Orbis and Orbis eras, types of submissions, or timeline metrics. WHAT QUESTION DID THIS STUDY ADDRESS? WHAT QUESTION DID THIS STUDY ADDRESS? We compiled a dataset of Project Orbis and non‐Orbis oncology applications for new drugs and therapeutic uses over a 6‐year period based on publicly available information from the FDA and Health Canada, and evaluated regulatory metrics. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? We identified shorter US‐vs.‐Canada submission and approval gaps for Orbis compared to non‐Orbis MAAs. Time to regulatory decision was aligned to expedited or standard review pathways in Canada. The times to regulatory decision for type A Orbis MAAs reviewed via priority review and standard submission pathways were similar. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? Compared to non‐Orbis MAA approvals, the most prominent difference in Orbis MAA approvals was a shorter submission gap between US and Canada, translating into earlier approvals in Canada. This study highlights insights derived from a comprehensive dataset of Project Orbis participation in Canada and lays groundwork for research evaluating time to patient access to treatment. Access to novel cancer drugs requires prior evaluation of benefit and risk, and regulatory authorization by a national health authority. The US Food and Drug Administration (FDA) Oncology Center of Excellence established Project Orbis in May 2019, providing a framework for international regulator collaboration to facilitate the concurrent submission and review of oncology products. The overall aim of Project Orbis is to enable earlier patient access to innovative cancer therapies. 1 Since its inception, Project Orbis has included authorities in Canada and Australia, and has since expanded to include Brazil, Israel, Singapore, Switzerland, and the United Kingdom. Health authorities in Europe and Japan participate as observers. 2 , 3 , 4 According to the FDA, to be eligible for Project Orbis, oncology products should be new active substances or indication extensions. Criteria include high impact, clinically significant applications that should generally qualify for FDA priority review because of improvement in safety and efficacy. 2 , 3 In Canada, new and supplemental new drug submissions (NDS, SNDS) for new uses are eligible for Project Orbis. 2 Regulatory decision timelines are driven mainly by review pathways governed by strength of the evidence as determined by Health Canada reviewers independently of Project Orbis participation. The two expedited review pathways in Canada are priority review and Notice of Compliance with conditions (NOC/c). 5 , 6 , 7 The three types of Project Orbis collaborations depend on the date of filing relative to the FDA (i.e., submission gap), as well as the extent of sharing of information and participation in review meetings: A (submission gap ≤1 month; sharing review information; attending multi‐country and FDA review meetings), B (submission gap >1 month; sharing review information; attending multi‐country and FDA review meetings), and C (any submission gap; sharing review information; no multi‐country review meetings; unlikely attendance at FDA review meetings). Each authority maintains decision‐making sovereignty. 1 , 2 , 3 , 8 , 9 , 10 , 11 We analyzed Project Orbis participation by Health Canada from 2019 to 2025. This analysis spanned regulatory submission and approval timing metrics, cancer type, and sponsor participation. To our knowledge, this work represents the most comprehensive evaluation to date of approvals associated with Project Orbis in Canada. METHODS Study design and data sources Data on Project Orbis marketing authorization applications (MAAs) approved by Health Canada were obtained from publicly available sources. 12 , 13 , 14 , 15 , 16 Based on Health Canada's Submission Under Review (SUR) list, we identified oncology MAAs approved from December 22, 2015 (first approval of an oncology drug in the SUR list) to December 31, 2025. We identified MAAs confirmed to participate in Project Orbis based on the FDA Project Orbis approvals dataset and the SUR list. The Orbis type classification was obtained from the SUR list and the descriptions of the corresponding Summary Basis of Decision (SBD) or Regulatory Decision Summary (RDS) for a given MAA. Orbis type classifications of select files were verified through an Access to Information request to Health Canada. In the case of discrepancies due to possible typographical errors (e.g., dates) in the data sources, the most plausible values were used. MAAs canceled or withdrawn by the sponsor, as well as MAAs for biosimilar or generic products, were excluded. Three Orbis MAAs reviewed by Health Canada as confirmatory SNDS were included. Analytical methods The dataset was separated into so‐called pre‐Orbis era (December 22, 2015–September 19, 2019) and Orbis era (September 20, 2019–December 31, 2025). The start of the Orbis era was defined as the date of the first Project Orbis approval in which Health Canada participated. Key regulatory metrics included submission gap (date of submission to Health Canada minus date of submission to the US FDA), time to regulatory decision (date of approval by Health Canada minus date of submission to Health Canada), and approval gap (date of approval by Health Canada minus date of approval by the US FDA). Additional metrics included the review time (date of approval by Health Canada minus date of acceptance into review by Health Canada) and screening time (date of acceptance into review by Health Canada minus date of submission to Health Canada). Nonparametric statistical analyses were performed for submission gap, time to regulatory decision, and approval gap. Comparisons among two groups were conducted using the Wilcoxon rank sum test. Statistically significant differences among at least three groups for a single independent factor were determined with a Kruskal–Wallis rank sum test, with Dunn's test for post‐hoc pairwise comparisons and Bonferroni P‐value adjustment. For multi‐factor testing, an aligned rank transform method was performed, followed by contrast tests with Bonferroni P‐value adjustment, using the ARTool package (version 0.11.2). A significance level of 0.05 was used for all analyses. All analyses were performed in R (version 4.4.2). RESULTS From the first oncology MAA approval on December 15, 2015 to the end of 2025, 362 oncology NDS or SNDS MAAs met the study criteria, including 97 Orbis MAAs and 161 non‐Orbis MAAs in the Orbis era, and 104 MAAs in the pre‐Orbis era (Figure 1 a ). Of the 138 Project Orbis MAAs approved by the FDA between September 2019 and December 2025, Health Canada participated in 102 (73.9%), including the 97 (70.3%) Orbis MAAs approved by Health Canada within the study period (Table S1 ). Orbis type in Canada differed from the estimated type based on FDA guidance in 26 (26.8%) cases (Figure S1 ). The number of Orbis MAAs increased steadily from 2019 to 2022 when Orbis MAAs represented approximately half of all oncology MAAs (Figure 1 b ; Figure S2 ). A higher proportion of Orbis MAAs utilized expedited review pathways than non‐Orbis MAAs (Figure 1 c ). Interestingly, 43 (44.3%) of Orbis MAAs were not reviewed through an expedited pathway. Descriptive analyses of the Health Canada marketing authorization applications (MAAs) dataset. (a) Flow diagram of oncology MAAs analyzed in the study. See Methods and Table S1 for details. (b) NDS and SNDS MAAs approved by Health Canada in the Orbis era, by non‐Orbis and Orbis types. (c) NDS and SNDS MAAs approved by Health Canada in the Orbis era, by non‐Orbis and Orbis types and submission pathway. Submission type: NDS, new drug submission; SNDS, supplemental new drug submission. Review directorate: BRDD, Biologic and Radiopharmaceutical Drugs Directorate; PDD, Pharmaceutical Drugs Directorate. Conditional submission pathway corresponds to Notice of Compliance with conditions (NOC/c). Other submission pathway includes standard review and pathway not specified. SUR, Health Canada submissions under review. Regulatory timeline metrics We hypothesized that Project Orbis MAAs approved by Health Canada would have a shorter submission gap and time to regulatory decision than non‐Orbis MAAs. The median submission gap was shorter for Orbis MAAs than for non‐Orbis MAAs (58.0 days (26.0–149.0) vs. 146.5 days (57.5–461.0); P < 0.0001), and also shorter than pre‐Orbis MAAs (132.5 days (61.0–345.8); P < 0.0001; Figure 2 a ). The trend toward shorter submission gap for Orbis compared with non‐Orbis was consistent for NDS and SNDS submission types, review directorates, priority reviews and standard reviews (Figure S3A–C ; Table S2 ). Regulatory metrics for NDS and SNDS marketing authorization applications approved by Health Canada in the pre‐Orbis and Orbis eras. (a, d) Submission gap, date of submission to Health Canada minus date of submission to the US FDA. (b, e) Time to regulatory decision (approval), date of approval by Health Canada minus date of submission to Health Canada. (c, f) Approval gap, date of approval by Health Canada minus date of approval by the US FDA. Horizontal lines represent the interquartile range, and vertical bars represent the median. Based on a Kruskal–Wallis rank sum test with Dunn's test for post‐hoc pairwise comparisons and Bonferroni P‐value adjustment: *P < 0.05, **P < 0.01, ****P < 0.0001. Conditional submission pathway corresponds to Notice of Compliance with conditions (NOC/c). Other submission pathway includes standard review and pathway not specified. Points beyond the axis ranges are not shown. As expected, the median submission gap was the shortest for Orbis type A MAAs (26.5 days (16.3–30.0)), followed by type B (70.5 days (31.0–91.8)) and type C (210.0 days (74.0–338.0)) (Figure S3D ). The median time to regulatory decision was shorter for Orbis MAAs than for non‐Orbis MAAs (265.0 days (200.0–329.0) vs. 342.0 days (277.0–357.0); P < 0.0001), and also shorter than for pre‐Orbis MAAs (296.0 days (224.0–347.0); P < 0.05; Figure 2 b ). The trend toward shorter time to regulatory decision for Orbis compared with non‐Orbis was consistent for NDS and SNDS submission types, review directorates, priority reviews, conditional reviews, and standard reviews (Figure S4A–C , Table S2 ). The median time to regulatory decision for Orbis MAAs reviewed under priority, conditional, and standard pathways was 203.0 days (188.5–211.0), 266.0 days (258.5–283.5), and 330.0 days (285.5–347.0), respectively, consistent with Health Canada's performance standards (215, 305, and 355 days, respectively) (Figure S4C ). 9 Interestingly, the median time to regulatory decision was shorter for Orbis type A and type B MAAs compared with non‐Orbis MAAs, as well as between Orbis type A MAAs (194.5 days (176.0–271.3)) and type B MAAs (263.5 days (207.0–334.5)), but not between type B MAAs and type C MAAs (287.0 days (258.0–343.0); Figure S4D , Table S2 ). We speculated that analysis of time to regulatory decision was confounded by priority, conditional, and standard review pathways. We next compared the dates of approval by FDA and Health Canada. The median approval gap was shorter for Orbis MAAs than for non‐Orbis MAAs (138.0 days (76.0–250.0) vs. 285.0 days (162.3–558.0); P < 0.0001), and pre‐Orbis MAAs (221.5 days (142.3–460.8); P < 0.001; Figure 2 c ). The trend toward shorter approval gap for Orbis compared with non‐Orbis was consistent for NDS and SNDS submission types, review directorates, and standard reviews, but not priority or conditional reviews (Figure S5A–C ). The median approval gap was the shortest for Orbis type A MAAs (72.5 days (43.8–113.8)), followed by type B (130.0 days (112.5–217.8)) and type C (299.0 days (164.0–471.0)), displaying a similar trend to the submission gap. A significantly shorter approval gap was observed between type A (P < 0.0001) and type B (P < 0.001) Orbis MAAs compared with non‐Orbis MAAs. Significantly shorter approval gaps were observed between Orbis type A and type C MAAs (P < 0.0001), and type B and type C MAAs (P < 0.01), but not between Orbis type C and non‐Orbis MAAs (P > 0.05) (Figure S5D ). Next, we investigated regulatory timeline metrics according to both Orbis type and review pathway. In general, time to regulatory decision within a given Orbis type was consistent with the Health Canada performance standard (Figure 2 e ). Notably, type A Orbis MAAs reviewed via priority review and other (including standard) submission pathways exhibited a similar time to regulatory decision (190.0 days (181.0–208.3) vs. 194.0 days (178.3–291.8), respectively). Similarly, the screening and review times for MAAs were consistent with Health Canada performance standards (Figure S6 , Table S3 ). 9 These metrics for type A Orbis MAAs reviewed via priority review and other (e.g., standard) submission pathways were similar. We analyzed MAAs in the Orbis era according to NDS/SNDS, priority/conditional/standard review, and Biologic and Radiopharmaceutical Drugs Directorate/Pharmaceutical Drugs Directorate (BRDD/PDD) review directorate. While acknowledging the small sample size in some subgroups, this analysis suggested that compared with non‐Orbis MAAs, Orbis MAAs exhibited shorter submission and approval gaps, but not necessarily time to regulatory decision (Figure S7 , Tables S4 , S5 ). In general, metrics for Orbis MAAs exhibited lower variability compared to non‐Orbis MAAs. Cancer type, sponsor, and drug class Among Orbis MAAs in Canada, the top five cancer types were lung, hematological, gastrointestinal, genitourinary, and breast (Figure S8A ). The top three sponsors were Merck (n = 18), AstraZeneca (n = 14), and Bristol Myers Squibb (n = 13) (Figures S8B , S9A ). At the anatomical therapeutic code class level 3, Orbis and non‐Orbis MAAs showed similar distributions, with monoclonal antibodies and antibody drug conjugates (L01F) being most prevalent, followed by protein kinase inhibitors (L01E) and other neoplastic agents (L01X) (Figure S9B ). DISCUSSION From 2019 to 2025, Health Canada approved 97 MAAs associated with Project Orbis. Overall, Orbis MAAs were associated with a shorter gap between submission to FDA and Health Canada, and by corollary, shorter time to regulatory decision. Regulatory decision timelines were generally aligned to Health Canada's priority, conditional, or standard review pathways. Type A Orbis MAAs reviewed by standard and priority review pathways had similar regulatory decision timelines. Notably, 26.8% of Orbis MAA types did not align to the Orbis type guidance, suggesting that Health Canada and/or sponsors exercise discretion. Time to regulatory decision was generally consistent with submission pathway. While type A MAAs had shorter median time to decision, the category also had the largest proportion reviewed under priority review (46.7%, 35.3%, and 27.3% in type A, B, and C, respectively). The similarity in median submission gap for non‐Orbis MAAs and Orbis type C MAAs suggests that type C MAAs may not derive the full potential benefits of the Orbis framework in terms of accelerating time to approval. Limitations of this study include that data were obtained from publicly available sources; therefore, the analysis did not account for benefit/risk profile, manufacturing (CMC) aspects, sponsor‐dependent factors such as requests for pause the clock, or sponsor or health authority efficiency/workload. Whether Project Orbis was associated with a reduction in redundant questions among participating partners or enhancement of submission quality could not be determined. Topics of future interest include comparing totality of evidence submitted to regulators, approved product labeling, and post‐marketing commitments. In Canada, Project Orbis research has focused on analysis of time to market and the relationship between regulatory approval and reimbursement. 17 , 18 , 19 In addition, studies have endeavored to quantify the initiative's effectiveness and therapeutic value of Project Orbis approvals. 8 , 20 Our study captures a broader scope, including pre‐Orbis MAAs as well as clinical and drug characteristics. Beyond Canada, an analysis across partner agencies demonstrated generally faster median approval time for Orbis relative to non‐Orbis new active substances, with lower submission gap variability across comparable agencies between 2019 and 2023. 8 In the first year of participation in the United Kingdom, which joined Project Orbis in 2021, all new cancer drugs reviewed under Project Orbis were approved earlier than in the European Union. 11 , 21 Similarly, in Switzerland, Project Orbis was associated with significantly reduced submission gap and review time for MAAs approved between 2020 and 2022. 10 In Canada, securing public patient access to new drugs and indications beyond regulatory approval involves health technology assessment (HTA) evaluation and pan‐Canadian Pharmaceutical Alliance negotiation. Understanding whether the association of Project Orbis with earlier authorization translates to earlier access remains to be understood. Based on an analysis of new active substances in 2022, Canadians wait an average of 736 days, or approximately 2 years, between Health Canada approval and the first listing in a provincial or territorial drug plan. 22 An analysis of Project Orbis drug approvals between 2019 and 2023 showed that only 72% of the Project Orbis Health Canada approvals were ultimately available to patients in Canada. 19 In 2025, the Government of Ontario (Funding Accelerated for Specific Treatments pilot program; FAST) and pan‐Canadian Pharmaceutical Alliance (Early Negotiation Process pathway; ENP) launched mechanisms for accelerating the funding and negotiation process specifically for Project Orbis drugs. 23 , 24 While basing eligibility on Project Orbis may be a practical starting point, not all clinically meaningful or innovative oncology drugs are reviewed through the initiative – in some cases due to sponsors' Canadian filing and launch strategies. Expanding accelerated reimbursement/negotiation criteria to include objective measures of improved clinical value (e.g., aligned to Health Canada's priority review and NOC/c pathways) could accelerate access to more innovative therapies. FUNDING This work was sponsored by AstraZeneca Canada Inc. CONFLICT OF INTEREST The authors are currently employed by AstraZeneca Canada Inc. JZ and DCS have stock ownership and/or other interests in the company. Preliminary results of this study were presented by JZ at the Drug Information Association (DIA) Canada Annual Meeting held in Gatineau, Quebec on October 27–28, 2025. AUTHOR CONTRIBUTIONS JZ and DCS wrote the manuscript; JZ and DCS designed the research; JZ performed the research; JZ and DCS analyzed the data. Supporting information Supplementary Information: Figures S1 to S9 and Tables S1 to S5. ACKNOWLEDGMENTS None. DATA AVAILABILITY STATEMENT The data used in this study are from publicly available sources. References Associated Data Supplementary Materials Supplementary Information: Figures S1 to S9 and Tables S1 to S5. Data Availability Statement The data used in this study are from publicly available sources.